SVRA CMO Form 3 shows 155,000 shares and option holdings

Rhea-AI Filing Summary

Savara Inc (SVRA) reported an insider ownership update as its Chief Medical Officer filed a Form 3. The filing lists 155,000 shares of common stock beneficially owned, noted to include RSUs that vest in full on December 4, 2025 (80,000) and December 12, 2026 (75,000), each representing a right to one share upon vesting.

Derivative holdings include stock options for 110,000 shares at $4.13 expiring December 11, 2033, vesting in sixteen equal quarterly installments from December 4, 2023, and options for 175,000 shares at $3.35 expiring December 12, 2034, vesting in sixteen equal quarterly installments from December 12, 2024.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wasfi Yasmine

(Last) (First) (Middle)

ONE SUMMIT SQUARE,

1717 LANGHORNE NEWTOWN ROAD, SUITE 300

(Street)

LANGHORNE PA 19047

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/17/2025

3. Issuer Name and Ticker or Trading Symbol
Savara Inc [ SVRA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	155,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	12/11/2033	Common Stock	110,000	$4.13	D
Stock Option (Right to Buy)	(3)	12/12/2034	Common Stock	175,000	$3.35	D

Explanation of Responses:

1. 80,000 represents RSUs that vest in full on December 4, 2025; and 75,000 represents RSUs that vest in full on December 12, 2026, in each case subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 4, 2023, subject to the reporting person's continued service with the Issuer.

3. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 12, 2024, subject to the reporting person's continued service with the Issuer.

	/s/ Kate McCabe as attorney-in-fact for Yasmine Wasfi	10/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Savara (SVRA) disclose in this insider filing?

The Chief Medical Officer filed a Form 3 reporting ownership of 155,000 common shares, RSUs vesting on specified dates, and two stock option positions.

How many Savara (SVRA) shares does the CMO beneficially own?

The filing shows 155,000 shares of common stock, including RSUs that vest on December 4, 2025 (80,000) and December 12, 2026 (75,000).

What stock options were reported by Savara’s (SVRA) CMO?

Options for 110,000 shares at $4.13 expiring December 11, 2033 and 175,000 shares at $3.35 expiring December 12, 2034.

What are the vesting schedules for the reported stock options?

Each option vests in sixteen equal quarterly installments, starting December 4, 2023 for the $4.13 option and December 12, 2024 for the $3.35 option.

What RSU details were included for Savara (SVRA)?

RSUs total 80,000 vesting on December 4, 2025 and 75,000 vesting on December 12, 2026, each representing a right to one common share upon vesting.

What is the role of the reporting person at Savara (SVRA)?

The reporting person is the company’s Chief Medical Officer.

What is the event date for this Savara (SVRA) ownership report?

The event date is October 17, 2025.